Nlrp3 Protein Inhibitors Pipeline Insight

DelveInsight’s, “NLRP3 Protein Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in NLRP3 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

NLRP3 Protein Inhibitors Understanding

NLRP3 Protein Inhibitors: Overview

The NLRP3 inflammasome regulates the release of pro-inflammatory cytokines in response to “danger signals,” including the presence of foreign or endogenous molecules that signal infection, tissue damage or metabolic imbalances. Chronic inflammation driven by improper activation of the NLRP3 inflammasome has been implicated in a wide array of diseases, including fibrotic, autoinflammatory and neurodegenerative diseases, as well as certain cancers. Small molecules that selectively inhibit NLRP3 have well-understood potential to address improper activation and treat chronic inflammation at the source, without broadly suppressing the immune system.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NLRP3 Protein Inhibitors R&D. The therapies under development are focused on novel approaches for NLRP3 Protein Inhibitors.

NLRP3 Protein Inhibitors Emerging Drugs Chapters

This segment of the NLRP3 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

NLRP3 Protein Inhibitors Emerging Drugs

 

SB206: Novan

SB206, is a topical antiviral gel for the treatment of viral skin infections. SB206 is currently being evaluated in B-SIMPLE4, a pivotal Phase 3 trial, for the treatment of treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipoxvirus.

 

NT-0167: Nodthera

NT-0167 is being evaluated in a Phase 1 clinical trial in healthy volunteers. Therapeutics that disrupt the NLRP3 inflammasome to inhibit damaging inflammatory processes have the potential to help patients with many chronic diseases. NodThera’s approach to selectively target the NLRP3 inflammasome without broadly suppressing the immune system is an enormously promising strategy for developing therapies that can help the patients

Further product details are provided in the report……..

NLRP3 Protein Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different NLRP3 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players working on NLRP3 Protein Inhibitors

There are approx. 12+ key companies which are developing the NLRP3 Protein Inhibitors. The companies which have their NLRP3 Protein Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novan.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

NLRP3 Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NLRP3 Protein Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NLRP3 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NLRP3 Protein Inhibitors drugs.

NLRP3 Protein Inhibitors Report Insights

  • NLRP3 Protein Inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

NLRP3 Protein Inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing NLRP3 Protein Inhibitors drugs?
  • How many NLRP3 Protein Inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NLRP3 Protein Inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NLRP3 Protein Inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for NLRP3 Protein Inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

NLRP3 Protein Inhibitors: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

NLRP3 Protein Inhibitors – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

SB206: Novan

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

DFV 890: Novartis

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

NT 0167: Nodthera

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

Research programme: NLRP3 inflammasome inhibitors - Roche

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

NLRP3 Protein Inhibitors Key Companies

NLRP3 Protein Inhibitors Key Products

NLRP3 Protein Inhibitors- Unmet Needs

NLRP3 Protein Inhibitors- Market Drivers and Barriers

NLRP3 Protein Inhibitors- Future Perspectives and Conclusion

NLRP3 Protein Inhibitors Analyst Views

NLRP3 Protein Inhibitors Key Companies

Appendix

List of Table

Table 1: Total Products for NLRP3 Protein Inhibitors

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for NLRP3 Protein Inhibitors

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Novan
• Novartis
• Nodthera
• Zydus Cadila
• Ventus Therapeutics
• Monte Rosa Therapeutics
• Roche
• Inflazome
• Ionis Pharmaceuticals
• TWi Biotechnology

 

Forward to Friend

Need A Quote